Background: Protect II study evaluated the effect of circulatory support with Impella vs Intra aortic balloon pump (IABP) in high risk patients undergoing high risk PCI with depressed LV function and complex anatomy. The results of the study were confounded by an imbalanced and more vigorous use of rotational atherectomy(RA) in the Impella arm which made the interpretation of the composite endpoint difficult. We sought to evaluate the safety and effectiveness of Impella 2.5 in high risk percutaneous coronary intervention (HRPCI) compared to the IABP in a more homogeneous population, without the confounding effect of RA. Methods: A total of 375 eligible patients underwent HRPCI without the use of rotational atherectomy (88% Protect II study). A composite of 10 major adverse events (MAE) endpoint including death, myocardial infarction, stroke, any repeat revascularization, was assessed at 30 and 90 days. Results: Baseline and procedural characteristics were balanced between the study arms: age 67 Ϯ10 years old, 86% CHF, 51% diabetes, 67% had prior myocardial infarction, and 26% renal insufficiency. The LVEF was 24Ϯ6, STS mortality was 5.6Ϯ6 and Syntax was 29Ϯ12. Patients treated with the Impella device had significant improved outcomes at 30 day and 90 day compared to IABP arm ( 29.3% vs 41.9%, pϭ0.011 and 35.5% vs 50.5%, pϭ0.003).
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PEPCAD-DES: A randomized, multicenter, single blinded trial comparing paclitaxel coated balloon angioplasty with plain balloon angioplasty in drugeluting-stent restenosis -12 months results
Harald Rittger 1 , Johannes Brachmann 2 , Matthias Waliszewski 3 , Ralf Birkemeyer 4 , Christoph Garlichs 1 , Jochen Wöhrle 5 1 Universitätsklinikum Erlangen, Medizinische Klinik 2, Erlangen, Germany, 2 Klinikum Coburg, Medizinische Klinik 2, Coburg, Germany, 3 B. Braun Vascular Systems, Melsungen, Germany, 4 Klinik für Kardiologie, Universitätsklinikum Rostock, Rostock, Germany, 5 Dept. of Cardiology, University of Ulm, Ulm, Germany, Ulm, Germany Background: We evaluated the impact of paclitaxel-coated balloon angioplasty for treatment of drug-eluting stent restenosis compared with uncoated balloon angioplasty alone. (NCT00998439). Methods: In this prospective, single-blind, multicenter, trial we randomly assigned 110 patients with Instent-Restnosis of drug eluting stents to undergo treatment either with paclitaxel coated balloon (SeQuent Please, BBraun, Melsungen) or balloon angioplasty alone. Primary endpoint was in-stent late lumen loss at 6 months. Secondary clinical endpoint was composited of cardiac death, myocardial infarction attributed to the target vessel or TLR. Results: There was no difference in patient baseline characteristics. Lesion length was 11.2Ϯ6.5mm in the DCB-and 12.2Ϯ8.2mm in the POBA-group (pϭn.s). Post PCI, for the stented segment and the total segment minimal lumen diameter and diameter stenosis were not different. Clinical follow-up after 12 months was 100%. Treatment with DCB was superior to balloon angioplasty alone with an in-stent late loss of 0.43Ϯ0.61mm vs. 1.03Ϯ0.77mm (pϽ0.001). Minimal lumen diameter was significantly larger and percent diameter stenosis significantly lower with use of the DCB for both the stented and total segment. Restenosis rate was reduced from 58.1% to 17.2% (PϽ0.001) and the clinical endpoint at 6 months was reduced from 50% to 16.7% (PϽ0.001), respectively. After 12 months the effect of DCB persisted (clinical endpoint 52.6% vs. 16.7%; pϽ0.001 and TLR 36.8% vs. 15.3%, pϭ0.005, respectively). There was one probable stent thrombosis in the POBA group. Clinical follow-up after 2 years will be completed in May 2013 and presented. Conclusions: Paclitaxel coated balloon angioplasty was superior to balloon angioplasty alone for the treatment of instent-restenosis of drug-eluting stents. The favorable effects of the DCB-therapy persisted over 12 months.
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Intravascular ultrasound-guided systematic two-stent techniques for coronary bifurcation lesions reduced late stent thrombosis and ST-elevation myocardial infarction
Shao Liang Chen 1 1 Nanjing First Hospital, Nanjing Medical University, Jiangsu, China Background: Effect of intravascular ultrasound (IVUS)-guided complex approaches using drug-eluting stent (DES) for coronary bifurcation lesions on clinical outcome has been not yet studied.The present study aimed to analyze the difference in one-year outcome after two-stent techniques with the implantation of DES for coronary bifurcation lesions between IVUS-guided versus angiography-guided groups. Methods : From May 26, 2007 to March 24, 2010 in Angio-guided group) were prospectively studied. We compared the major adverse cardiac event (MACE, including cardiac death, stent thrombosis [ST], myocardial infarction[MI], target lesion/vessel revascularization)at 12-month follow-up, before and after adjusting by using propensity score matching. Results: By 12-month after indexed procedure, patients in the Angio-guided group had significantly increased in-stent restenosis. The unadjusted late ST rate was 6.9%, 5.3% and 4.3% in the Angio-guided group was 4.3%, significantly different to 0.6% in the IVUS-guided group (pϭ0.003),1.2% 0.6% and this translated into the significant differences in overall (6.9% vs. 1.2%, pϽ0.001) and definite (5.3% vs. 0.6%, pϽ0.001) ST, MI (8.9% vs. 4.6%, pϭ0.038) and cardiac death (3.3% vs. 0.9%, pϭ0.049) between two groups. By propensity score matching, 123 paired patients were matched, the late ST at 12-month follow-up was 4.9% in Angio-guided group, and it was 0% in the TUESDAY, OCTOBER 23, 10:30 AM-12:30 PM 
